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Summary 
The chemical pollutants that are regulated under international 
and EU legislation represent a very small fraction of the universe of 
chemicals that occur in the environment as a result of human 
activities. So far, most regulating and implementation bodies, 
responsible for water and wastewater treatment, are working on the 
assumption that the so-called priority pollutants are responsible for 
the most significant share of environmental, human health and 
economic risk, even though they are representing a minor fraction of 
the universe of both known and yet-to be identified chemicals. Thus, 
the study of the fate of the emerging pollutants and their 
transformation products in wastewater-treatment plants (WWTP) is 
of paramount importance. 
As the power of analytical chemistry increases, the types of 
chemicals that can be detected increase, and the limits of 
concentration at which they can be measured are continually 
lowered. With respect to obtaining a holistic view of risk, target-
based environmental monitoring should necessarily be accompanied 
by non-targeted analysis using high resolution hybrid mass 
spectrometers. 
The main objective of this research is the contribution to the 
current knowledge on the actual burden of micropollutants on the 
aquatic environment and comprehensive conclusions will be reached 
for the possible measures to be taken for its future protection.  
The investigation carried out has a significant practical interest 
and application since the results can be directly used by authorities 
and operators of WWTPs. 
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Introduction 
Contamination of water bodies has been the spotlight of 
scientific community concerning the preservation and sustainability 
of the environment. Due to the advances of analytical chemistry, a 
great number of regulated and non-regulated compounds are 
detected in wastewater samples. Emerging contaminants is the term 
for compounds that are newly released in the environment or have 
recently been discovered by water quality controls and have yet to be 
studied. The EPs encompass a diverse group of compounds, for which 
nowadays many information are available. However, only a small 
proportion of the chemical compounds have been sufficiently 
monitored in the water bodies (Loos et al., 2013). 
The determination of organic contaminants in environmental 
samples constitutes a great challenge, since many matrix components 
may interfere the analysis and mostly due to the increased number of 
compounds with various physico-chemical properties. The most 
common choice for the determination of EPs are multi-residue 
methods, including however only a few hundreds of compounds. This 
automatically reveals a gap in environmental analysis concerning 
methods and techniques that can analyze simultaneously a great 
number of emerging pollutants. Multi-residue, wide-scope screening 
methods offer this possibility, for the determination of more analytes. 
The development of high resolving power mass analyzers (HRMS) 
has contributed a lot towards the wide-scope screening of analytes 
(Hernandez et al., 2012) and more complete information on 
undesirable compounds present in the sample is feasible.  
HRMS full scan acquisition technique offers the possibility of 
retrieving all the information concerning the analytes in post-
acquisition approaches. Furthermore, HRMS is continually evolving, 
giving the possibility for quantitative analysis with constantly 
increasing sensitivity. Limited linear range, traditionally attributed to 
QTOF systems because of saturation effects, has been overcome by 
modern instruments (Aguera et al., 2013). 
The main approaches for post-acquisition data evaluation are 
target, suspect and non-target screening (Krauss et al., 2010). The 
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main difference between the first approach and the latter ones is the 
presence of reference standard available.  
The aims of this project have 2 main directives. The first study 
will try to identify the organic loading that end up in water bodies, by 
3 main workflows in order to cover the majority of compounds 
present in the samples. In the second part, we try to extend our 
knowledge not only to emerging pollutants, but also to their 
transformation products and metabolites, that are formed during the 
wastewater treatment and may be of risk to human or the 
environment. 
The first study is a comprehensive quantitative target 
screening of emerging pollutants in environmental samples, which 
involves a generic sample preparation, a UPLC-QTOF-MS/MS method 
and post-acquisition evaluation of the data. An in-house database 
was built with information of retention time, MS and MS/MS ions for 
2327 compounds, including pesticides, pharmaceuticals, drugs of 
abuse, industrial chemicals, doping compounds, as well as some 
metabolites and transformation products. Optimization was 
performed in order to minimize false negative results and a 
validation protocol is proposed in order to evaluate the performance 
criteria of the HRMS method. The method was applied in an influent 
and an effluent wastewater from a wastewater treatment plant of 
Greece. Additional emerging pollutants were detected by suspect 
screening, where specific validated workflow was applied for the 
identification of human metabolites of well consumed drugs. Non-
target screening was the last step to identify compounds that are 
abundant in the samples and yet no previous knowledge existed. 
In the second study, batch experiments were conducted in the 
laboratory to simulate the processes during the wastewater 
treatment plant. Biotransformation and chlorination of analytes that 
are removed during the treatment was performed in order to find out 
whether more toxic transformation products are formed. 
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Samples 
Influent and effluent wastewater samples, as well as sludge 
samples were collected from the WWTP of Athens (Greece) during 
two sampling campaigns conducted on 2014 and 2015.  
The WWTP of Athens is designed with primary sedimentation, 
activated sludge process with biological nitrogen and phosphorus 
removal and secondary sedimentation. The average sewage flow for 
the periods of study was 720,000 m3 day-1 for a typical dry day. For 
the load calculations the specific day flow has been used. As for the 
travel distances of wastewater in the sewer, the closest connected 
household is 0.5 km and the most remote is 30 km away. The 
residential population connected to the WWTP based on official 
census excluding the commuters is 3,700,000 and the number of 
people estimated based on number of house connections is 
4,562,500. This WWTP has a design capacity to serve a population 
equivalent of 5,200,000, being by far the largest of Greece and one of 
the largest in the world. For the drug use estimations, we used the 
census value for the residential population. 
In each campaign influent and effluent wastewater samples 
(24-hour composite flow proportional samples) were collected 
during 7 consecutive days from 11/3 to 18/3 in 2014 and from 4/3 
to 11/3 in 2015. Moreover, the respective sludge for each day was 
also collected in plastic bags. 
 This allows investigation of drug use trends throughout the 
week and the partitioning of the analytes on particulate matter. All 
wastewater samples were collected in pre-cleaned high-density 
polyethylene (HDPE) bottles. Untreated and treated wastewater 
samples were immediately filtered with glass fiber filters (pore size 
0.7 μm) after arrival at the laboratory. Samples were stored in the 
dark at 4 °C until analysis. 
 
 
  
TREMEPOL                                               Deliverable 5.2 
10 
 
1st Study- Target, Suspect & Non-target Screening 
Analysis and Evaluation of the data 
 Optimization was performed in order to minimize false 
negative results and a validation protocol is proposed in order to 
evaluate the performance criteria of the HRMS method. Analytes 
were extracted from wastewater sample by mixed-bed SPE protocol 
(Bletsou et al., 2015) and from sludge sample with solid-liquid 
extraction (Gago-Ferrero et al., 2015a). The samples were analyzed 
and evaluated with sophisticated software. Identification points were 
attributed to each analyte and quantitation was also carried out. 
 
Results in wastewater 
Target Analysis 
Reversed-Phase (RP) liquid chromatography 
The optimized and validated method was applied to influent 
and effluent wastewater samples from the wastewater treatment 
plant of Athens. For the identification of the compound, studying the 
MS spectrum, the retention time, mass accuracy criteria should be 
met, gaining thus 2 IPs. When studying the MS/MS spectrum, if 
fragments are also available, additional 2.5 IPs are earned. For 
screening of the compounds, at least 2 (≥ 2) IPs are required, and for 
identification at least 4 (≥ 4) IPs. In Table 1, all the detected analytes 
in influent and effluent are presenting, accompanied by the 
identification points earned. 
In total, 371 compounds were detected in the samples; 338 in 
influent wastewater and 301 in effluent wastewater. In influent 
wastewater, 219 compounds were identified, earning at least 2 IPs, 
and the rest 188 were identified with additional MS/MS information. 
61 pesticides were detected, 205 drugs, including pharmaceuticals, 
illicit and drugs of abuse, 4 sweeteners, 10 perfluorinated 
compounds (PFCs), 8 aminoacids, 47 transformation products and 
other chemicals. In effluent wastewater, 192 compounds were 
identified and the 109 were identified. 51 pesticides were present, 
191 drugs, 4 sweeteners, 11 PFCs, 4 aminoacids, 49 transformation 
products and other chemicals. It is worth mentioning that more TPs 
are detected in effluent wastewater, because they are formed 
through the wastewater procedure in the plant.  
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This is the first study reported the presence of 371 organic 
micropollutants in wastewaters, belonging in various classes. 66 
pesticides, belonging to different classes were detected in total. 29 
stimulants, most of them being amphetamine derivatives and 9 
sympathomimetics (ephedrine derivatives) are reported. Moreover 9 
anesthetics, closely related to lidocaine, which is well reported in the 
literature, are present in the samples. Various other drugs are 
identified, categorized as drugs against high blood pressure, 
cardiovascular diseases, diuretics, anti-diabetics, antiviral, anti-
histamin, etc. This categorization, as presented in Table 1 can provide 
a valuable and holistic information for the consumption of drugs in 
the area of Athens. 
 
Table 1. Quantitative results of wastewater samples 
 
Compound Name CAS number 
influent wastewater effluent wastewater 
IPs C (μg/L) IPs C (μg/L) 
 
Pesticides  
1 Acetochlor 34256-82-1 2.5 0.0003 2.5 0.0002 
2 Dimethachlor 50563-36-5 2 0.07 n.d. 
 
3 Dimethachlor-ESA - 2.5 2.0 2.5 1.1 
4 Dimethachlor-OXA 1086384-49-7 2.5 0.54 2 0.09 
5 Metolachlor 51218-45-2 5 0.002 5 0.007 
6 Metolachlor-ESA 171118-09-5 2.5 0.43 2.5 0.05 
7 Diuron 330-54-1 ≥5 0.011 ≥5 0.02 
8 Fenuron 101-42-8 n.d. 
 
2 0.088 
9 Difenoxuron 14214-32-5 2.5 0.02 2.5 0.19 
10 Diflubenzuron 35367-38-5 2.5 0.005 n.d. 
 
11 Fluometuron 2164-17-2 ≥5 0.58 ≥5 13.56 
12 Metobromuron 3060-89-7 2 0.004 n.d. 
 
13 Dimethoate 60-51-5 2 0.03 2 0.04 
14 Fludioxonil 131341-86-1 2.5 0.005 2 0.004 
15 Cyprodinil 121552-61-2 n.d. 
 
2 0.002 
16 Flutolanil 66332-96-5 2 0.01 2 0.01 
17 Fipronil 120068-37-3 ≥5 0.02 ≥5 0.01 
18 Fipronil sulfone 120068-36-2 2.5 0.0012 2.5 0.002 
19 Imidacloprid 138261-41-3 2 0.02 5 0.12 
20 Terbutryn 886-50-0 2 0.003 2.5 0.0006 
21 Prometryn (Caparol) 7287-19-6 2 0.04 2 0.04 
22 Thiodicarb 59669-26-0 2 0.009 2.5 0.04 
23 Propamocarb 24579-73-5 2.5 0.010 2.5 0.004 
24 Dioxacarb 6988-21-2 2 0.004 n.d. 
 
25 Isoprocarb 2631-40-5 2.5 0.003 n.d. 
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26 Iprovalicarb 140923-17-7 n.d. 
 
2 0.02 
27 
Methiocarb 
(Mercaptodimethur) 
2032-65-7 2 0.01 n.d. 
 
28 Propham 122-42-9 2.5 0.05 2.5 0.08 
29 Temephos 3383-96-8 2.5 0.45 n.d. 
 
30 Pirimiphos-methyl 29232-93-7 2 0.01 4.5 0.02 
31 Monocrotophos 6923-22-4 2 0.01 n.d. 
 
32 Carbendazim 10605-21-7 2 0.01 2 0.02 
33 Carbofuran-3-hydroxy 16655-82-6 5 0.02 2.5 0.007 
34 Chlormequat 7003-89-6 2.5 0.02 4.5 0.007 
35 Napropamide 15299-99-7 2 0.007 2 0.02 
36 Climbazole 38083-17-9 5 0.15 ≥5 0.19 
37 Difenoconazole 119446-68-3 2 0.01 n.d. 
 
38 Penconazole 66246-88-6 2 0.03 ≥5 0.09 
39 Cyproconazole 94361-06-5 n.d. 
 
2 0.02 
40 Fluconazole 86386-73-4 ≥5 0.09 ≥5 0.75 
41 Thiabendazole 148-79-8 2 0.010 2.5 0.01 
42 Atrazine 1912-24-9 2 0.03 n.d. 
 
43 Atrazine-desisopropyl 1007-28-9 2.5 0.16 2.5 0.39 
44 Simazine 122-34-9 2 0.05 2.5 0.11 
45 Azoxystrobin 131860-33-8 ≥5 0.60 ≥5 1.9 
46 Azoxystrobin acid 1185255-09-7 5 0.04 ≥5 0.09 
47 Dalapon 75-99-0 2.5 0.01 n.d. 
 
48 Dazomet 533-74-4 2.5 0.05 2.5 0.11 
49 Dikegulac 18467-77-1 2 0.0003 n.d. 
 
50 Famoxadone 131807-57-3 2 0.0006 n.d. 
 
51 Imazapyr 81334-34-1 2 0.01 2.5 0.01 
52 Methoxyfenozide 161050-58-4 4.5 0.21 ≥5 0.94 
53 
N-2,4-
Dimethylphenylformamide 
(DMF. Metabolite Amitraz) 
60397-77-5 2.5 0.008 2 0.0004 
54 
Naptalam (N-1-
Naphthylphthalamicacid) 
132-66-1 n.d. 
 
2.5 0.06 
55 Thiamethoxam 153719-23-4 2.5 0.0006 5 0.01 
56 Cycloheximide  66-81-9 2.5 0.11 n.d. 
 
57 Carboxin 5234-68-4 2.5 0.0009 n.d. 
 
58 Oxycarboxin 5259-88-1 2.5 0.01 2 0.011 
59 Picaridin (Icaridin) 119515-38-7 2 0.03 2 0.07 
60 DEET (Diethyltoluamide) 134-62-3 5 0.07 5 0.02 
61 Metalaxyl 57837-19-1 ≥5 0.003 ≥5 0.08 
62 Amitrole 61-82-5 2.5 1.17 2 0.04 
63 Dinoterb 1420-07-1 5 0.03 2.5 0.01 
64 Fluazifop 69335-91-7 2.5 0.02 2.5 0.05 
65 Propoxur 114-26-1 ≥5 0.003 ≥5 0.003 
66 Piperonyl butoxide 51-03-6 ≥5 0.11 2 0.003 
 
Opiates,  opioids  
67 Morphine 57-27-2 ≥5 0.64 2 0.0012 
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68 Normorphine 466-97-7 2.5 0.02 n.d. 
 
69 Methadone (METH) 76-99-33 2 0.08 2.5 0.04 
70 Codeine (COD) 76-57-3 2 0.04 5 0.44 
71 Norcodeine 467-15-2 n.d. 
 
2.5 0.08 
72 EDDP  30223-73-5 2 0.12 2 0.10 
73 Hydrocodone 125-29-1 n.d. 
 
2.5 0.02 
 
Stimulants- Amphetamins 
74 Cocaine (COC) 50-36-2 5 0.11 n.d. 
 
75 Benzoylecgonine (BECG) 519-09-5 ≥5 0.30 2 0.05 
76 
Ecgonine methyl ester 
(EME) 
7143-09-01 2 0.11 n.d. 
 
77 Amphetamine 300-62-9 ≥5 0.27 n.d. 
 
78 Methamphetamine (MA) 537-46-2 2.5 0.07 n.d. 
 
79 Dimethylamphetamine 1009-69-4 2.5 0.12 2.5 0.95 
80 Ethylamphetamine 457-87-4 2 0.18 2.5 1.3 
81 
3,4-methylenedioxy-
amphetamine (MDA) 
4764-17-4 ≥5 2.1 2 0.22 
82 
3,4-methylenedioxy-N-
methylamphetamine 
(MDMA) 
42542-10-9 2 0.16 2 0.09 
83 
PMMA (para-Methoxy-N-
methylamphetamine) 
3398-68-3 5 6.1 5 19 
84 
Metaraminol (3,β-
dihydroxyamphetamine) 
337376-15-5 2.5 1.2 n.d. 
 
85 
Pholedrine (p-hydroxy-
methylamphetamine) 
6114-26-7 n.d. 
 
2.5 1.1 
86 4-methyl-2-hexanamine 105-41-9 2 0.59 2 0.11 
87 Mephentermine  100-92-5 2 0.74 2.5 0.97 
88 Phenelzine 51-71-8 2 3.6 2.5 0.75 
89 Pyrovalerone 3563-49-3 n.d. 
 
2.5 0.31 
90 Phendimetrazine 17140-98-6 2 0.46 2 0.26 
91 Midodrine 133163-28-7 2 0.20 2.5 1.08 
92 Heptaminol 372-66-7 2.5 0.49 2.5 0.64 
93 Cathine/ norpseudoephedrine 492-39-7 2.5 0.12 2.5 0.05 
94 Nikethamide 59-26-7 n.d. 
 
2.5 0.72 
95 Pemoline 2152-34-3 2 0.05 n.d. 
 
96 Aminorex 2207-50-3 2 0.43 2 2.23 
97 Dimefline 1165-48-6 n.d. 
 
2.5 0.46 
98 Ethamivan 304-84-7 n.d. 
 
≥5 0.48 
99 
TMA 
(trimethoxyamphtamine) 
1082-23-1 2 0.26 2 0.26 
100 
3,4-DMA 
(dimethoxyamphtamine) 
120-26-3 2 0.22 2 0.17 
101 
4-Methyl-pyrrolidino-
propiophenone (MPPP) 
28117-80-8 2 0.01 2 0.01 
102 
2 C-D (2,5-dimethoxy-4-
methylphenethylamine) 
24333-19-5 2 3.41 2.5 1.41 
 
Sympathomimetics  
103 Ephedrine 299-42-3 ≥5 0.34 ≥5 0.03 
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104 Norephedrine 492-41-1 2.5 0.82 ≥5 0.22 
105 Etafedrine 48141-64-6 2.5 0.02 2.5 0.12 
106 Metanephrine 5001-33-2 2.5 0.005 n.d. 
 
107 Phenylephrine 1416-03-1 n.d. 
 
2 0.01 
108 
Apophedrin  
(Phenylethanolamine) 
7568-93-6 5 0.07 5 0.03 
109 Isoetharine 7279-75-6 2.5 0.01 2.5 0.03 
110 Methoxamine 337376-15-5 2 0.00 2.5 0.02 
111 Nylidrin 447-41-6 2.5 0.00 2 0.01 
 
Hallucinogenic (cannabinoids)  
112 
Δ9-Tetrahydrocannabinol 
(THC) 
1972-08-3 n.d. 
 
2 0.01 
 
Benzodiazepines tranquilizers  
113 Alprazolam 92623-85-3 2 0.03 ≥5 0.04 
114 Clobazam 22316-47-8 2 0.009 2 0.001 
115 Diazepam 439-14-5 2.5 0.04 2.5 0.04 
116 Nordiazepam 1088-11-5 2.5 0.008 2.5 0.009 
117 7-amino-flunitrazepam 34084-50-9 2 0.03 2 0.04 
118 Lorazepam 846-49-1 n.d. 
 
2.5 0.01 
119 Midazolam 59467-70-8 n.d. 
 
2 0.02 
120 temazepam 846-50-4 ≥5 0.03 5 0.03 
121 Oxazepam 604-75-1 2.5 0.01 2.5 0.02 
 
Barbiturates  
122 Phenobarbital 50-06-6 2 0.01 2.5 0.02 
123 Primidone 125-33-7 n.d. 
 
2.5 0.10 
124 Bemegride 64-65-3 2.5 0.68 2 0.05 
 
Antipsychotics  
125 Clozapine 5786-21-0 2 0.15 2 0.08 
126 Quetiapine 111974-69-7 ≥5 0.02 2 0.01 
127 Amisulpride 71675-85-9 ≥5 0.07 ≥5 0.07 
128 Amisulpride-N-Oxide 71675-85-9 2 0.004 5 0.01 
129 Sulpiride 15676-16-1 ≥5 0.04 ≥5 0.08 
130 Haloperidol 52-86-8 2.5 0.0001 ≥5 0.0005 
131 Risperidone 106266-06-2 n.d. 
 
2 0.003 
132 
Paliperidone (9-OH-
Risperidone) 
147687-18-1 n.d. 
 
2 0.01 
133 Buspirone  36505-84-7 ≥5 0.02 n.d. 
 
134 Levomepromazine sulfoxide 7052-08-6 2 0.09 2.5 0.09 
 
Antiepileptic  
135 Carbamazepine 298-46-4 5 0.61 ≥5 1.7 
136 
Carbamazepine-10,11-
epoxid 
36507-30-9 5 0.19 4.5 0.25 
137 10-Hydroxycarbamazepine 29331-92-8 5 0.42 5 1.00 
138 Oxcarbazepine 28721-07-5 5 0.04 5 0.05 
139 Topiramate 97240-79-4 5 0.40 ≥5 0.61 
140 Lamotrigine 84057-84-1 ≥5 0.06 2.5 1.6 
141 Levetiracetam 102767-28-2 ≥5 0.59 2.5 0.12 
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142 Valproic acid 99-66-1 2.5 25 2.5 0.18 
143 Phenytoin 57-41-0 n.d. 
 
2 0.03 
 
Antidepressants  
144 Amitriptyline 50-48-6 ≥5 0.23 5 0.11 
145 Nortriptyline 894-71-3 2 0.004 2 0.01 
146 Doxepine 1668-19-5 2 0.05 2 0.04 
147 Mirtazapine 61337-67-5 ≥5 0.33 ≥5 0.49 
148 8-OH-Mirtazapine - 2.5 0.09 n.d. 
 
149 Desmethyl mirtazapine 61337-68-6 2 0.03 2 0.04 
150 Maprotiline 10262-69-8 2 0.01 n.d. 
 
 
SSRIs (serotonin replacing inhibitors)  
151 Citalopram 59729-33-8 ≥5 1.0 ≥5 1.0 
152 Norcitalopram 144025-14-9 ≥5 0.23 ≥5 0.32 
153 Sertraline 79617-96-2 2 0.10 2.5 0.02 
154 Fluoxetine 54910-89-3 2.5 0.10 2.5 0.07 
 
SNRIs (serotonin-norepinephrine reuptake inhibitors)  
155 Duloxetine 116539-59-4 n.d. 
 
2.5 0.005 
156 Venlafaxine 93413-69-5 ≥5 0.92 ≥5 2.0 
157 Venlafaxine-N-oxide 1094598-37-4 2 0.01 2.5 0.06 
158 N,O- bisdesmethylvenlafaxine 135308-74-6 5 0.12 5 0.16 
159 N-Desmethylvenlafaxine 149289-30-5 4.5 1.9 5 6.5 
160 O-desmethylvenlafaxine 93413-62-8 ≥5 0.89 ≥5 1.1 
 
Anesthetics  
161 Benzocaine 94-09-7 2 0.01 n.d. 
 
162 Bupivacaine 38396-39-3 2 0.004 n.d. 
 
163 Lidocaine 137-58-6 2.5 0.17 2.5 0.69 
164 Mepivacaine 96-88-8 2.5 
 
n.d. 
 
165 Prilocaine  721-50-6 2 0.005 2.5 0.006 
166 Procaine 59-46-1 2.5 0.002 2.5 0.006 
167 Para-fluorofentanyl 90736-23-5 2 0.002 2.5 0.004 
168 Norfentanyl 1609-66-1 n.d. 
 
2.5 0.001 
 
Antiviral  drugs  
169 Amantadine 768-94-5 5 0.06 5 0.09 
170 Atazanavir 198904-31-3 2.5 0.02 2.5 0.05 
171 Darunavir 206361-99-1 5 0.15 5 0.10 
172 Ritonavir 155213-67-5 ≥5 0.014 2.5 0.009 
173 Emtricitabine 143491-57-0 5 0.33 5 0.15 
174 Tenofovir 147127-20-6 2.5 0.30 n.d. 
 
 
Hypertension- diuretic  drug  
175 Aliskiren 173334-57-1 ≥5 0.27 ≥5 0.25 
176 Valsartan 137862-53-4 ≥5 0.66 5 0.92 
177 Candesartan 139481-59-7 2 0.29 2 0.42 
178 Telmisartan 144701-48-4 2.5 0.22 5 0.18 
179 Verapamil 52-53-9 2.5 0.02 2 0.02 
180 D617 (met. of verapamil) 34245-14-2 5 0.07 5 0.10 
181 Eprosartan 133040-01-4 5 0.84 2.5 0.22 
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182 Irbesartan 138402-11-6 2 0.40 2 0.40 
183 Diltiazem 42399-41-7 5 0.10 5 0.07 
184 Nordiltiazem - ≥5 0.03 2.5 0.02 
185 Deacetyldiltiazem 42399-40-6 5 0.13 5 0.28 
186 Phenoxybenzamine 59-96-1 2.5 0.41 2.5 0.45 
187 Furosemide  54-31-9 ≥5 0.03 2.5 0.03 
188 Hydrochlorothiazide 58-93-5 ≥5 0.28 ≥5 0.32 
189 Bendroflumethiazide 73-48-3 2.5 0.01 n.d. 
 
190 Acetazolamide 59-66-5 5 0.03 5 0.004 
191 Amiloride 2016-88-8 2 0.05 2.5 0.03 
192 Chlorthalidone 77-36-1 n.d. 
 
2 0.008 
 
Antidiabetic drugs  
193 Sitagliptin 486460-32-6 ≥5 0.48 n.d. 
 
194 Vildagliptin 274901-16-5 5 0.29 5 0.51 
195 Pioglitazone 111025-46-8 2 0.004 2 0.004 
196 Lacosamide 175481-36-4 4.5 0.02 5 0.04 
197 Nateglinide 105816-04-4 2 0.005 n.d. 
 
198 Metformin 657-24-9 ≥5 93 ≥5 35 
199 Guanylurea 926-72-7 2 0.74 ≥5 5.0 
 
Antihistamine  
200 Hydroxyzine 68-88-2 2.5 0.004 n.d. 
 
201 Cetirizine 83881-52-1 ≥5 0.14 5 0.18 
202 Chlorpheniramine 132-22-9 2.5 0.01 2.5 0.008 
203 Crotamiton 483-63-6 2.5 0.01 5 0.01 
204 Diphenhydramine 58-73-1 ≥5 0.04 ≥5 0.04 
205 Orphenadrine 83-98-7 ≥5 0.05 ≥5 0.04 
206 
Nororphenadrine  
(Tofenacin, Elamol) 
15301-93-6 2 0.007 2.5 0.01 
 
Antiulcer 
207 Cimetidine 51481-61-9 2 0.07 2.5 0.50 
208 Ranitidine 66357-35-5 ≥5 2.6 ≥5 1.0 
209 Ranitidine-S-oxide 73851-70-4 2 0.17 2.5 0.11 
 
Cardiovascular diseases -intravascular  
210 Rosuvastatin  287714-41-4 2.5 0.17 2 0.13 
211 Atorvastatin 134523-00-5 ≥5 1.5 n.d. 
 
212 Gemfibrozil 25812-30-0 ≥5 0.24 2 0.05 
213 Fenofibric acid  49562-28-9 ≥5 0.61 2 0.30 
214 Propafenone 54063-53-5 ≥5 0.56 ≥5 0.53 
215 Iopromide 73334-07-3 ≥5 1.6 ≥5 0.94 
216 Clopidogrel Carboxylic acid 144457-28-3 ≥5 0.60 ≥5 0.56 
 
CNS stimulants  
217 Caffeine 58-08-2 ≥5 9.6 5 3.0 
218 
Paraxanthin  
(1,7-dimethylxanthine) 
611-59-6 ≥5 5.9 ≥5 0.92 
219 
Theophylline 
(1,3-dimethylxanthine) 
58-55-9 ≥5 2.0 n.d. 
 
220 Pentoxyfylline *6493-05-06 5 0.64 n.d. 
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221 Nicotine 54-11-5 ≥5 13.0 ≥5 0.93 
222 Cotinine 486-56-6 5 9.1 5 0.54 
223 Hydroxycotinine 34834-67-8 ≥5 11.8 2.5 0.07 
 
Analgesics-NSAIDs 
224 O-N-bisdesmethyltramadol - 2.5 0.02 2.5 0.02 
225 O-desmethyltramadol 73986-53-5 2.5 0.03 5 0.01 
226 N-desmethyltramadol 75377-45-6 2.5 0.01 2.5 0.01 
227 Tramadol-N-oxide 147441-56-3 2 0.10 2.5 0.12 
228 Salicylic acid 69-72-7 5 5.4 ≥5 0.14 
229 Paracetamol 103-90-2 ≥5 4.8 2.5 0.14 
230 4-Acetamidoantipyrine 83-15-8 5 0.07 5 0.09 
231 4-Formylaminoantipyrine 1672-58-8 2.5 0.02 ≥5 0.03 
232 
Isopyrin (4-Isopropyl-
aminoantipyrine) 
3615-24-5 n.d. 
 
2.5 0.02 
233 Meptazinol 54340-58-8 n.d. 
 
2.5 0.003 
234 Pethidine 57-42-1 2 0.001 2.5 0.003 
235 Salicylamide 65-45-2 2 0.01 2.5 0.11 
236 Diclofenac 15307-86-5 2.5 0.08 n.d. 
 
237 Fenbufen 36330-85-5 ≥5 1.7 5 0.39 
238 Fenoprofen 29679-58-1 2.5 5.1 2.5 2.0 
239 Flufenamic acid 530-78-9 2.5 0.02 2.5 0.03 
240 Flurbiprofen 51543-39-6 2 0.48 n.d. 
 
241 Ibuprofen 15687-27-1 ≥5 1.1 n.d. 
 
242 Indoprofen 31842-01-0 2 0.22 n.d. 
 
243 Ketoprofen 22071-15-4 2.5 0.11 n.d. 
 
244 Meclofenamic Acid  644-62-2 2.5 0.02 n.d. 
 
245 Mefenamic acid 61-68-7 5 0.51 5 0.05 
246 Naproxen 22204-53-1 5 0.93 2 0.05 
247 Niflumic acid 4394-00-7 ≥5 0.14 ≥5 0.27 
248 Nimesulide 51803-78-2 n.d. 
 
2.5 0.098 
249 Sulindac 38194-50-2 2 0.002 n.d. 
 
250 Oxaprozin  21256-18-8 2.5 0.44 n.d. 
 
251 Antipyrine /Phenazone 60-80-0 n.d. 
 
2 0.05 
 
beta-blockers 
252 Albuterol 18559-94-9 2 0.005 2.5 0.02 
253 Atenolol 29122-68-7 ≥5 1.65 ≥5 1.07 
254 
Atenolol acid  
(Metoprolol acid) 
63659-18-7 5 0.47 ≥5 0.12 
255 Betaxolol 63659-18-7 2 0.008 n.d. 
 
256 Bisoprolol 66722-44-9 ≥5 0.03 ≥5 0.07 
257 Carteolol 51781-06-7 2.5 0.002 n.d. 
 
258 Celiprolol 56980-93-9 ≥5 0.42 ≥5 0.33 
259 Metoprolol  37350-58-6 5 0.81 ≥5 1.3 
260 Pindolol 13523-86-9 2 0.001 n.d. 
 
261 Propranolol 525-66-6 5 0.13 2.5 0.21 
262 Salbutamol 18559-94-9 2.5 1.2 2.5 0.72 
263 Sotalol 3930-20-9 5 0.43 5 0.55 
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264 Esmolol 103598-03-4 2.5 0.002 2.5 0.01 
 
Antibiotics  
265 Azithromycin 83905-01-5 2.5 0.03 ≥5 0.06 
266 Roxithromycin 80214-83-1 5 0.02 2 0.03 
267 Clarithromycin 81103-11-9 ≥5 2.7 ≥5 2.4 
268 N-desmethyl Clarithromycin 101666-68-6 ≥5 0.72 5 0.93 
269 Sulfadiazine 68-35-9 5 0.04 5 0.02 
270 N4-Acetylsulfadiazine 127-74-2 2.5 0.07 2.5 0.46 
271 Sulfadimidine 57-68-1 2 0.0008 5 0.005 
272 
N4-Acetylsulfamethazine 
(N4-Acetylsulfadimidine) 
100-90-3 2 0.03 2.5 0.08 
273 Sulfamethoxazole 723-46-6 5 0.09 ≥5 0.36 
274 N4-Acetylsulfamethoxazole 21312-10-7 2.5 0.03 2 0.02 
275 Sulfapyridine 144-83-2 ≥5 0.03 ≥5 0.06 
276 Trimethoprim 738-70-5 5 0.06 ≥5 0.41 
277 Linezolid 165800-03-3 2 0.03 2.5 0.06 
278 Metronidazole 443-48-1 2.5 0.17 5 0.13 
279 Ternidazol 1077-93-6 2 0.03 n.d. 
 
280 Nigericin 28380-24-7 2 0.41 2.5 0.84 
281 Levamisole 14769-73-4 2 0.06 ≥5 0.10 
 
Antibacterial  -  veterinary drugs  
282 Enrofloxacin 93106-60-6 2.5 0.02 n.d. 
 
283 Marbofloxacin 115550-35-1 2 0.05 n.d. 
 
284 Triclocarban 101-20-2 2 0.11 2.5 0.35 
285 Triclosan 3380-34-5 2 0.08 2.5 0.08 
286 Decoquinate 18507-89-6 n.d. 
 
2 0.099 
 
Anticonvulsant  
287 Pregabalin 148553-50-8 5 0.68 5 0.45 
288 Gabapentin 60142-96-3 ≥5 0.79 ≥5 0.24 
289 Warfarin 81-81-2 2.5 1.9 n.d. 
 
 
Chemotherapeutic-ant i-cancer drugs  
290 Cytarabin 147-94-4 2 0.90 n.d. 
 
291 Ifosfamide 3778-73-2 2.5 0.10 2.5 0.28 
292 Cyclophosphamide 50-18-0 2.5 0.009 2.5 0.03 
 
Other drugs  
293 Memantine 19982-08-2 2.5 0.04 2.5 0.06 
294 Acamprosate 77337-76-9 2 0.52 2 0.84 
295 Fluocinolone acetonide 67-73-2 n.d. 
 
2.5 0.01 
296 Benserazide 14919-77-8 2 0.48 2 1.47 
297 Benzamidine 618-39-3 2.5 0.70 2 0.65 
298 dextromethorphan 125-71-3 n.d. 
 
2 0.0017 
299 Vigabatrin 60643-86-9 2 0.18 n.d. 
 
300 Guaifenesin 93-14-1 2.5 0.56 n.d. 
 
301 Piracetam 7491-74-9 2.5 0.03 2.5 0.33 
 
Steroids 
302 17β-Estardiol (E2) 50-28-2 2.5 0.59 2.5 0.60 
303 Prednisolone 50-24-8 2.5 2.2 n.d. 
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304 Drostanolone metabolite - 2.5 0.02 2.5 0.03 
305 Mesterolone metabolite - 2.5 0.07 2.5 0.13 
306 Progesterone 57-83-0 2.5 1.71 n.d. 
 
307 19-Norandrosterone 1225-01-0 n.d. 
 
2.5 1.04 
308 
allo-THF 
(Allotetrahydrocortisol) 
302-91-0 2.5 1.47 n.d. 
 
309 THE (Tetrahydrocortisone) 200-161-9 ≥5 0.98 n.d. 
 
310 THF (Tetrahydrocortisol) 53-02-1 2.5 2.8 n.d. 
 
 
PFCs 
311 PFBuS 375-73-5 2.5 0.007 5 0.006 
312 PFDeA 335-76-2 5 0.05 2 0.04 
313 PFHpA 375-85-9 2 0.006 2 0.006 
314 PFHps 335-77-3 2.5 0.0007 2 0.0005 
315 PFHxA 307-24-4 2 0.002 5 0.004 
316 PFHxS 355-46-4 2.5 0.005 2 0.004 
317 PFNA 375-95-1 2 0.010 2 0.01 
318 PFOA 2395-00-8 ≥5 0.008 5 0.006 
319 PFOS 1763-23-1 2.5 0.03 2.5 0.004 
320 PFPeA 2706-90-3 2 0.002 4.5 0.002 
321 PFUnA 2058-94-8 n.d. 
 
2 0.0003 
 
sweeteners  
322 Acesulfame  33665-90-6 ≥5 1.9 ≥5 0.64 
323 Cyclamate 139-05-9 5 24 2.5 1.0 
324 Saccharine 81-07-2 2.5 3.1 2.5 0.011 
325 Sucralose 56038-13-2 2.5 0.60 2.5 0.98 
 
Industrial  Chemicals  
326 Benzotriazole (BTR) 95-14-7 2 0.04 5 0.49 
327 1-Hydroxy-Benzotriazole 2592-95-2 2 0.17 2.5 0.16 
328 4-Hydroxy-Benzotriazole 26725-51-9 2 0.27 2.5 0.64 
329 
4-Me-Benzotriazole/ 
5-Me Benzotriazole 
29385-43-1 2 0.0009 ≥5 1.2 
330 Benzothiazole (BTH) 95-16-9 2.5 0.05 2.5 0.07 
331 2-Amino-Benzothiazole 136-95-8 ≥5 0.07 ≥5 0.09 
332 2-Me-S-Benzothiazole 615-22-5 ≥5 0.06 ≥5 0.03 
333 2-OH-Benzothiazole 934-34-9 2 0.15 2.5 0.21 
334 4-tert-octylphenol (4-t-OP) 27193-28-8 ≥5 1.2 ≥5 0.51 
335 4-nonylphenol (4-NP) 104-40-5 ≥5 0.07 2 0.03 
336 
4-Nonylphenol-mono-
ethoxylate 
104-35-8 2 0.01 2 0.004 
337 Melamine 108-78-1 2 0.65 2 0.66 
338 Bisphenol A 80-05-7 5 0.03 n.d. 
 
339 Benzenesulfonamide 98-10-2 2.5 0.12 2 0.07 
340 o-toluenesulfonamide 88-19-7 2 0.13 2 0.09 
341 Galaxolidone - 2.5 0.59 2.5 0.60 
342 Diethyl phthalate 84-66-2 5 2.0 5 1.8 
343 Dimethyl phthalate 131-11-3 2.5 0.02 2.5 0.02 
344 Di-n-butyl phthalate 84-74-2 5 0.33 5 1.1 
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345 Benzyl butyl phthalate 85-68-7 ≥5 0.05 ≥5 0.08 
346 Triethylphosphate 78-40-0 2.5 0.05 5 0.05 
347 Triphenyl phosphate (TPP) 115-86-6 5 0.05 5 0.12 
348 
Benzophenon 3 
(2-Hydroxy-4-
methoxybenzophenon) 
131-57-7 2.5 1.5 n.d. 0.20 
349 Prolinamide 51-06-9 2 4.1 2 1.5 
350 Benzoic acid 65-85-0 2.5 49 2.5 29 
351 2-Aminobenzimidazole 934-32-7 n.d. 
 
2.5 0.13 
352 Tributylamine 102-82-9 2.5 0.008 2.5 0.01 
353 
Benzyl-dimethyl-
dodecylammonium 
139-07-1 2 0.07 n.d. 
 
354 
Didecyldimethylammonium 
(DADMAC (C10:C10)) 
2390-68-3 2 0.02 2 0.01 
355 2-aminoheptane 123-82-0 5 0.64 2 0.16 
356 4-Piperidin carboxamide 39546-32-2 2 1.0 2 0.95 
357 Ethyl sulfate 540-82-9 2.5 3.6 2 1.3 
 
Aminoacids -  Naturally occurring compounds  
358 Alanine (Ala) 56-41-7 2.5 11 n.d. 
 
359 g-aminobutiric acid (GABA) 56-12-2 2.5 7.2 2.5 13 
360 Glutamic acid (Glu) 56-86-0 2 13 2 4.5 
361 Methionine (Met) 63-68-3 2.5 2.3 2 0.06 
362 Proline (Pro) 147-85-3 2 7.8 n.d. 
 
363 Serine (Ser) 56-45-1 2 2.8 n.d. 
 
364 Valine (Val) 72-18-4 ≥5 59 2 48 
365 Leucine (Leu) 328-39-2 2.5 12 n.d. 
 
366 Adenosine 58-61-7 ≥5 0.61 2.5 0.58 
367 Resveratrol 501-36-0 2.5 0.11 2.5 0.12 
368 1,4-butanediol (1,4 BD) 110-63-4 2 0.0006 n.d. 
 
369 2-Phenylphenol 90-43-7 2.5 0.09 n.d. 
 
370 Dimethylaniline 95-68-1 2.5 0.02 n.d. 
 
371 2-Phenethylamine 64-04-0 2.5 0.09 2 0.12 
 
Quantification of the analytes was performed, as well. As 
shown in Table 1, the concentrations of the analytes range in influent 
from 93 μg/L (metformin) to 0.14 ng/L (haloperidol) and in effluent 
from 48 μg/L (valine) to 0.22 ng/L (acetochlor). In Figure 1, the 
distribution of the concentrations of the analytes from the sub-ng 
level until some mg is presented. Apart from metformin, also valproic 
acid and caffeine are the most abundant drugs in influent 
wastewater. In effluent, metformin together with its metabolite 
gualynurea and N-desmethylvenlafaxine present the higher 
concentrations. For pesticides, most abundant compounds were 
fluometuron, azoxystrobin and a metabolite of dimethachlor, both in 
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influent and effluent wastewaters. Sweeteners are also present in 
high concentration (0.6 μg/L sucralose to 24 μg/L cyclamate), but 
they are removed more than 60 % during the treatment. Benzoic acid 
is the most abundant from the rest of the chemicals, at 
concentrations 49 μg/L and 29 μg/L in influent and effluent 
wastewater, respectively. It is mainly used mostly in the production 
of other chemicals. An interesting chemical that is present in high 
concentrations is ethyl sulfate, which is a minor metabolite of human 
after alcohol consumption (Rodríguez-Álvarez et al., 2014). 
Aminoacids are not emerging pollutants, but they are present in 
wastewater in very high concentrations. In influent, the 
concentrations are above 2 μg/L for the aminoacids detected and 
while significant removal is observed, in effluent, valine and g-
aminobutiric acid (GABA) are at concentrations over 10 μg/L. 
 
Figure 1. Distribution of concentration of analytes detected in samples 
 
Hydrophilic interaction liquid chromatography (HILIC) 
Hydrophilic interaction liquid chromatography (HILIC) has 
been a valuable complementary, orthogonal approach to reverse 
phase (RP) chromatography. Hyphenated to high resolution mass 
spectrometry it can provide additional information and selectivity for 
the target screening of polar micropollutants in the environment. 
Additional to the RP-QToF-MS/MS method, a HILIC-QToF-
MS/MS method was developed, optimized and validated for the 
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determination of 902 polar and semi-polar micropollutants in 
wastewater samples. In Table 2, the additional compounds that are 
detected only in HILIC method are presented. 
 
Table 2. Additional compounds detected in wastewater samples after the 
application of HILIC method 
1 1-(3-Trifluoromethylphenyl)-piperazine 
2 2-Methyl-4-amino-6-methoxy-s-triazine 
3 2-Naphthalene sulfonic acid 
4 
3 4-methylenedioxy-N-ethylamphetamine 
(MDEA)  
5 3 phenoxy benzoic acid 
6 3,5,6 trichloro-2-pyridinol 
7 4-nonylphenoxy acetic acid 
8 4-Trifluoromethylphenol 
9 5,6-di-Me-Benzotriazole 
10 6-methyl-2-thiouracil 
11 Amineptine 
12 Amlodipine 
13 Ancymidol 
14 Aspartame 
15 Atomoxetin 
16 Atrazine-desethyl 
17 Bamethane 
18 Benzylamphetamine 
19 Benzylpiperazine (BZP)  
20 Bufexamac 
21 Capsaicine 
22 
Carbamazepine-10-11-dihydro-10-11-
dihydroxy 
23 Cefalexin 
24 Cefazolin 
25 Chlrothalonil-4-hydroxy 
26 Cimaterol 
27 Clindamycin 
28 Clopidol 
29 Cloranolol 
30 Clorprenaline 
31 Crotethamide 
32 Cyclobenzaprine 
33 Cyromazine 
34 Hydrocodone  
35 Deprenyl-N-oxide 
36 Desipramine 
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37 Dexamethasone 
38 Diflunisal 
39 Dimethyldioctadecyl ammonium 
40 Dimoxystrobin 
41 Dinotefuran 
42 Diprophylline 
43 Doxylamine 
44 Dropropizine 
45 Eplerenone 
46 Etilefrine 
47 Etodolac 
48 Exemestan 
49 Fenproporex  
50 Fenspiride 
51 Fluorometholone 
52 Fluoxymesterone 
53 Hydromorphone 
54 Hyoscine 
55 Irgarol 
56 Isproturon- didemethyl 
57 Ketamine 
58 Levallorphan 
59 Lidocaine-N-oxide 
60 LMG 
61 Lovastatin 
62 Mabuterol 
63 Mazindol 
64 Meclofenoxate 
65 Mefenorex 
66 Mephedrone 
67 Mephenesine 
68 Metamitron desamino 
69 Methotrexate 
70 Methoxyphenamine 
71 Metipranolol 
72 Nadolol 
73 Naphazoline 
74 Nefopam 
75 N-ethyl-4-methoxybenzamide 
76 N-bisdesmethyl tramadol 
77 N-N-Didesmethylvenlafaxine 
78 Tramadol 
79 Norfenefrine  
80 Octopamine  
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81 Norbuprenorphine 
82 Norfenfluramine 
83 Norketamine 
84 Norlidocaine 
85 Nornicotine 
86 Oseltamivir carboxylate 
87 Procainamide 
88 Oxilofrine  
89 Oxprenolol 
90 Oxycodone (OC) 
91 Oxymetazoline 
92 Pencyclovir 
93 Pentylenetetrazol  
94 Phenylalanine (Phe) 
95 Phenylbutazone 
96 Prolinamide 
97 Prolintane 
98 Propachlor-OXA 
99 Propazine-2-hydroxy  
100 Propionylpromazine 
101 Propoxycaine 
102 Propylhexedrine 
103 Pyrilamine 
104 Pyrimidinol 
105 Ritalinic acid 
106 Rivastigmin 
107 Stanozolol 
108 Sudan II 
109 Sulfamoxole 
110 Sulfanilamide 
111 Terbutaline 
112 Tiamulin 
113 Tolnaftat 
114 Torasemide 
115 Tralkoxydim 
116 Triamterene 
117 Triethylamine  
118 Trimeprazine 
119 Trimethylamine 
120 Tripropylamine 
121 Tryptamine 
122 Tyramine 
123 Tyrosine (Tyr) 
124 Ursodeoxycholic acid 
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125 Vedaprofen 
126 Zidovudine 
127 Zonisamide 
128 Zopiclone 
 
 
Communication of the achieved levels of confidence for Suspect 
& Non-target Screening 
The system presented by Schymanski et al. (2014) to 
communicate the level of confidence achieved in the identification of 
the detected compounds was used. Level 1 corresponds to confirmed 
structures where a reference standard is available, level 2 to 
probable structures, level 3 for tentative candidate(s), Level 4 to 
unequivocal molecular formulas and level 5 to exact mass(es) of 
interest.  
 
Suspect Screening 
Suspect screening of the influent wastewater samples using the 
“metabolite suspects” yielded 1660 hits in positive ESI mode (PI) and 
864 in negative mode (NI) applying only accuracy threshold (2 mDa). 
After the application of filtering steps this number decreased to 79 
hits (PI, corresponding to 37 compounds) and 71 hits (NI, 
corresponding to 21 substances). The 37 and 21 substances (PI and 
NI, respectively) remaining were then investigated closer according 
to steps 6 and 7 above (presence of characteristic adducts and 
spectral interpretation). After the evaluation of all steps, 13 suspect 
compounds were tentatively identified that fulfilled all criteria, all of 
them in PI. None of the evaluated substances was tentatively 
identified in NI, most probably due to the lower sensitivity of this 
operational mode. The identified suspects are given in Table 3. In 
cases of Level 1 Identification Confidence, which means that 
reference standard was purchased for confirmation, the analyte was 
also included in the target database, as well. 
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Table 3. Details on the 13 suspect metabolites. 
Name, Structure and Formula Parent Exp. tR 
(Pred. tR)
a 
Additional Evidenceb Level 
Atenolol acid 
O OH
OH
O
N
CH3
CH3
H
 
C14H21NO4 
Atenolol 5.1 (5.5) -Similarity 0.92 with 
MassBank record EA069710c. 
-Confirmation with standard 
1 
Amisulpride-N-oxide 
S CH3
NH2O
CH3
O
NH
N
+
CH3 OO
O
-
C17H27N3O5S1 
Amisulpride 5.6 (6.5)  
- Confirmation with standard 
1 
N-desmethyl clarithromycin 
CH3
OH
CH3
OH
CH3 CH3
O
O
O
CH3
O
CH3 O
CH3
O CH3
O
OH
NH
CH3
O
CH3
O
CH3
CH3
OH
CH3
 
C37H67NO13 
Clarithromyci
n 
10.1 (9.6) -Intra-day trend consistent 
with the parent compoundd 
-Intra-week trend consistent 
with the parent compounde  
-Confirmation with standard 
 
1 
Hydroxyclarithromycin 
CH3
OH
CH3
OH
CH3 CH3
O
O
O
CH3
O
CH3 O
CH3
O CH3
O
OH
NH
CH3
O
CH3
O
CH3
CH3
OH
CH3
OH
 
C38H69NO14 
Clarithromyci
n 
8.5 (9.2) -Intra-day trend consistent 
with the parent compoundd 
-Intra-week trend consistent 
with the parent compounde  
3 
Hydroxynicotine 
N
N
CH3
HO
 
C10H14N2O2 
Nicotine 3.1 (2.3) - 3 
Cotinine 
O
N
CH3
N  
C10H12N2O 
Nicotine 4.9 (5.1) -Similarity 0.99 with 
MassBank record 
WA000998c 
-Confirmation with standard 
1 
Hydroxycotinine 
OH
O N N
CH3  
Nicotine 3.9 (4.0) - HILIC/RP elution supports 
propertiesf 
-Confirmation with standard 
1 
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C10H12N2O2 
Nornicotine 
NH
N  
C9H12N2 
Nicotine 2.5 (2.6) -Similarity 0.77 with NIST 
record 1185301b 
-Feasible tR
c 
2b 
Ranitidine-S-oxide 
S
O
O O
-
O
N N
N
N
+
CH3
CH3
CH3
H
H
C13H22N4O4S1 
Ranitidine 2.0 (2.9) -Intra-week trend consistent 
with the parent compounde  
-Confirmed with reference 
standard 
1 
Tramadol-N-oxide 
CH3
N
+
CH3
H
O
CH3
OH
O
-
 
C16H25NO3 
Tramadol 6.0 (8.0) -Intra-week trend consistent 
with the parent compounde  
2b 
N-desmethyl venlafaxine 
OH O
N
CH3
CH3
H
 
C16H25NO2 
Venlafaxine 7.4 (6.3) -Similarity 0.96 with 
MassBank record EA103410c 
-Intra-day trend consistent 
with the parent compoundd 
-Intra-week trend consistent 
with the parent compounde  
-Confirmation with standard 
 
2a 
O-desmethyl venlafaxine 
CH3
N
CH3
OH
OH
 
C16H25NO2 
Venlafaxine 6.0 (6.4) -Similarity 0.98 with 
MassBank record EA105304c 
-Intra-day trend consistent 
with the parent compoundd 
-Intra-week trend consistent 
with the parent compounde  
-Confirmation with standard 
 
2a 
Guanylurea 
O
NN
N
N
H
H
H H
H
H
 
C2H6N4O 
Metformin 1.3 (1.2) - HILIC/RP elution supports 
propertiesf 
Confirmation with standard 
 
1 
 
Mass spectra were available for several of these compounds, 
allowing the assignment of a confidence level of 2a initially where the 
measured spectra matched the database spectra.  
Where mass spectra were not available in libraries, other 
evidence was pursued to increase the confidence of the suspect 
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identification. The spectrum of the tentatively identified metabolite 
was compared with that of the parent compound. 
The complementary nature of HILIC and RP elution as well as 
the presence in influent and effluent samples was also exploited in 
the identification of suspect analytes.  
The intra-day concentration profile of parent and metabolites 
can also be used to provide additional evidence for the identification. 
Similar conclusions were reached from the comparison of the intra-
week concentration profiles among parent compounds and related 
metabolites.  
 
Non-target Screening 
The non-target screening approach was applied to masses 
selected from among the most intense masses detected in the 
influent wastewaters from the WWTP of Athens. The workflow 
applied for the identification of non-target compounds is presented 
by Gago-Ferero et al. (2015b). 
Table 4 and 5 summarizes the results obtained for 25 of the 
highest intensity masses detected in negative and positive ionization 
mode, respectively. 
 
Table 4. Details on non-target compounds in ESI(-) mode. 
m/z 
Unequivocal 
molecular 
formula 
tR  
Pred. 
tR 
Level Adduct  Tentative Candidate 
Individual substances Levels 1-3 
94.02970 
C5H5NO  
(3-hydroxy 
pyridine) 
3.3 4.2 1 [M-H]- 
 
151.0404 
C8H8O3 
(Phenoxy acetic 
acid) 
3.6 5.5 2ª [M-H]- 
 
199.0439 
C9H12O3S  
(4-Isopropyl 
benzene 
sulfonic acid) 
5.3 5.1 3 [M-H]- 
CH3
CH3
SOH
O
O  
204.1244 
C9H19NO4 
(Panthenol) 
3.3 4.1 1 [M-H]- 
 
Glycol ether sulfates (GES) 
N
OH
O
OH
O
CH3
CH3
OH
O
NH OH
OH
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m/z 
Unequivocal 
molecular 
formula 
tR  
Pred. 
tR 
Level Adduct  Tentative Candidate 
229.0376 
C6H14O7S 
(2GES) 
1.8 3.6 2b [M-H]- 
n=2 
273.0650 
C8H18O8S 
(3GES) 
2.4 3.8 2b [M-H]- 
n=3 
317.0900 
C10H22O9S 
(4GES) 
2.9 4.4 2b [M-H]- 
n=4 
361.1162 
C12H26O10S 
(5GES) 
3.2 5.2  2b [M-H]- 
n=5 
405.1422 
C14H30O11S 
(6GES) 
3.5 6.1* 2b [M-H]- 
n=6 
449.1689 
C16H34O12S 
(7GES) 
3.7 6.7* 2b [M-H]- 
n=7 
493.1955 
C18H38O13S 
(8GES) 
3.9 7.2* 2b [M-H]- 
n=8 
537.2217 
C20H42O14 
(9GES) 
4.1 7.6* 2b [M-H]- 
n=9 
581.2470 
C22H46O15S 
(10GES) 
4.3 7.9* 2b [M-H]- 
n=10 
625.2729 
C24H50O16S 
(11GES) 
4.4 8.1* 2b [M-H]- 
n=11 
669.2990 
C26H54O17S 
(12GES) 
4.5 8.2* 2b [M-H]- 
n=12 
713.3259 
C28H58O18S 
(13GES) 
4.6 8.2* 2b [M-H]- 
n=13 
Linear Alkylbenzyl Sulfonates (LAS) and SulfoPhenyl Alkyl Carboxylic acids (SPACs) 
297.1530 
C16H26O3S 
(C10-LAS) 
11.5 11.7 2a§  [M-H]- 
 
311.1684 
C17H28O3S 
(C11-LAS) 
12 12.1 
2a§ 
 
[M-H]- 
 
325.1842 
C18H30O3S 
(C12-LAS) 
12.5 12.3 1 [M-H]- 
 
O
O
OH
S
O
O
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O
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S
O
O
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O
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m/z 
Unequivocal 
molecular 
formula 
tR  
Pred. 
tR 
Level Adduct  Tentative Candidate 
299.0965 
C14H20O5S 
(SPA-8C) 
4.8 7.2  
3 
 
[M-H]- 
 
Remaining substances (Levels 3-5) 
121.0291 C7H6O2 2.8  4 [M-H]- 57 hits chemspider 
121.0290 C7H6O2 4.5  4 [M-H]- 57 hits Chemspider 
186.1139 C9H17NO3 3.3  4 [M-H]- 789 hits Chemspider 
405.1436 C14H29O11S 3.5  3 [M-H]- 
Branched isomer of hexaglycol ether 
sulfate 
Pred. tR: predicted retention time; *Out of the applicability domain of the tR prediction 
model; §mix of isomers (spectra present in MassBank as a mix of isomers). 
 
Table 5. Details on non-target compounds in ESI(+) mode. 
m/z 
Unequivocal 
molecular 
formula  
tR  
Pred. 
tR 
Level  Adduct  Tentative Candidate 
Confirmed non-targets 
96.0452 C5H5NO 2.27 2.9 1 [M+H]
+ 
 
195.1233 
C8H18O5 
(4-PEG) 
4.19 6.2 1 [M+H]+ 
 
Polyethylene glycol suspects 
239.1489 
C10H22O6 
(5-PEG) 
4.8 6.8 3 [M+H]+ 
 
 
300.2016 
C12H26O7 
(6-PEG) 
5.16 7.3 3 [M+NH4]
+ 
 
344.2278 
C14H30O8 
(7-PEG) 
5.4 7.6 3 [M+NH4]
+ 
 
388.2541 
C16H34O9 
(8-PEG) 
5.6 7.8 3 [M+NH4]
+ 
 
432.2803 
C18H38O10 
(9-PEG) 
5.8 8.0 3 [M+NH4]
+ 
 
476.3065 
C20H42O11 
(10-PEG) 
5.9 8.2 3 [M+NH4]
+ 
 
520.3327 
C22H46O12 
(11-PEG) 
6.13 8.3 3 [M+NH4]
+ 
 
N
OH
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m/z 
Unequivocal 
molecular 
formula  
tR  
Pred. 
tR 
Level  Adduct  Tentative Candidate 
564.3589 
C24H50O13 
(12-PEG) 
6.3 8.4 3 [M+NH4]
+ 
 
608.3851 
C26H54O14 
(13-PEG) 
6.44 8.5 3 [M+NH4]
+ 
 
652.4113 
C28H58O15 
(14-PEG) 
6.6 8.6 3 [M+NH4]
+ 
 
696.4376 
C30H62O16 
(15-PEG) 
6.7 8.7 3 [M+NH4]
+ 
 
740.4638 
C32H66O17 
(16-PEG) 
6.9 8.8 3 [M+NH4]
+ 
 
784.49 
C34H70O18 
(17-PEG) 
7 8.9 3 [M+NH4]
+ 
 
Remaining non-targets (Level 4 and Level 5) 
145.0977 C6H12N2O2 1.91  4 [M+H]
+ 523 hits Chemspider 
149.1176 C7H16O3 5.73  4 [M+H]
+ 103 hits Chemspider 
191.1647 C10H22O3 9.4  4 [M+H]
+ 106 hits Chemspider 
135.1018 C6H14O3 4.68  4 [M+H]
+ 106 hits Chemspider 
164.1282 C7H17NO3 1.28  5 *  
232.1913 C12H25NO3 9.1  5 *  
316.1955 4 possibilities 12.69  5   
358.2078 3 possibilities 5.09  5   
374.2390 7 possibilities 5.24  5   
424.1857 12 possibilities 4.98  5   
468.2108 6 possibilities 5.2  5   
Pred. tR: predicted retention time.*The identity of the adduct could not be confirmed. 
  
TREMEPOL                                               Deliverable 5.2 
32 
 
Retrospective suspect screening of surfactants 
As a high number of tentatively identified surfactant 
substances of different types were among the most intense peaks, the 
presence of surfactants, originally found as non-targets, was studied 
in detail through retrospective suspect screening using the 
surfactants list described above.  
In total, 82 substances out of 398 suspects were tentatively 
identified, as shown in Table 6. 38 out of these 82 compounds were 
tentatively identified with MS/MS evidence and 44 without MS/MS 
evidence, but with additional information (plausible tR and 
chromatographic peak shape among the homologue series), 
supporting their presence.  
Ten compounds from the SPCs class of surfactants were 
identified. Other groups of surfactants were identified similarly, 
including DATS (7 substances tentatively identified), LAS (4 
substances tentatively identified), AS (4 substances tentatively 
identified), AEOs (13 substances tentatively identified) or DEAs (3 
substances tentatively identified).  
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Table 6. Suspect surfactants results 
Color code: 
GREEN: Tentatively identified. tR is plausible among the analogue series (also in HILIC) + MS/MS match with MassBank, MS/MS is consistent with one 
of the analogues present in MassBank or at least is plausible according to the structure. 
ORANGE: Tentatively identified. tR is plausible among the analogue series (also in HILIC) but there was not possible to obtain MS/MS information 
because of the intensity of the peaks. We consider them tentatively identified also based on chromatographic criteria and the information present in 
other studies. 
RED: No evidences. No MS/MS information. 
Suspect surfactants results - Negative ESI mode:  
Name Neutral formula 
Monoisotopic 
mass 
RP tR (min)  
HILIC tR 
(min) 
Plausible tR 
among the 
analogue series 
MS/MS 
data 
available 
MS/MS 
plausibility 
Tentatively 
identified 
C5-DATS C11H14O3S1 225.0591 7.4 1.21 Yes Yes Yes YES 
C8-DATS C14H20O3S1 267.1060 10.5 1.75 Yes No n.e. YES 
C9-DATS C15H22O3S1 281.1217 11 1.73 Yes Yes Yes YES 
C10-DATS C16H24O3S1 295.1373 11.8 1.71 Yes Yes Yes* YES 
C11-DATS C17H26O3S1 309.1530 12.3 1.70 Yes Yes Yes YES 
C12-DATS C18H28O3S1 323.1686 12.9 1.67 Yes Yes Yes YES 
C13-DATS C19H30O3S1 337.1843 13.4 n.d. Yes No n.e. YES 
C15-DATS C21H34O3S1 365.2156 6 n.d. No No No NO 
 
  
  
 
 
  
C10-LAS C16H26O3S1 297.1530 12.5 1.65 Yes Yes YES YES 
C11-LAS C17H28O3S1 311.1686 13.0 1.55 Yes Yes YES YES 
C12-LAS C18H30O3S1 325.1843 13.6 1.42 Yes Yes YES YES 
C13-LAS C19H32O3S1 339.1999 14.1 1.37 Yes Yes YES YES 
 
  
  
 
 
  
C4-SPC C10H12O5S1 243.0333 1.8 7.02 Yes Yes Yes YES 
C5-SPC C11H14O5S1 257.0489 2.3 6.58 Yes Yes Yes YES 
C6-SPC C12H16O5S1 271.0646 4.7 6.24 Yes Yes Yes YES 
C7-SPC C13H18O5S1 285.0802 5.3 5.24 Yes Yes Yes* YES 
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Name Neutral formula 
Monoisotopic 
mass 
RP tR (min)  
HILIC tR 
(min) 
Plausible tR 
among the 
analogue series 
MS/MS 
data 
available 
MS/MS 
plausibility 
Tentatively 
identified 
C8-SPC C14H20O5S1 299.0959 6.0 4.33 Yes Yes Yes* YES 
C9-SPC C15H22O5S1 313.1115 6.7 4.07 Yes Yes Yes YES 
C10-SPC C16H24O5S1 327.1272 7.6 3.38 Yes Yes Yes* YES 
C11-SPC C17H26O5S1 341.1428 8.6 3.32 Yes Yes Yes YES 
C12-SPC C18H28O5S1 355.1585 9.3 n.d. Yes Yes Yes YES 
C13-SPC C19H30O5S1 369.1741 8.5 n.d. No No n.e. NO 
C13-SPC C19H30O5S1 369.1741 10.1 n.d. Yes Yes Yes YES 
C15-SPC C21H34O5S1 397.2054 10.2 n.d. No No n.e. NO 
 
  
  
 
 
  
C12-AS C12H26O4S1 265.1479 11.2 1.24 Yes Yes Yes* YES 
C13-AS C13H28O4S1 279.1636 12.8 1.21 Yes Yes Yes YES 
C14-AS C14H30O4S1 293.1792 13.6 1.21 Yes Yes Yes YES 
C15-AS C15H32O4S1 307.1949 11.8 1.20 No No n.e. NO 
C16-AS C16H34O4S1 321.2105 14.5 1.20 Yes Yes Yes YES 
 
  
  
 
 
  
C12-AE1S C14H30O5S1 309.1741 10.7 n.d. No Yes No NO 
C12-AE1S C14H30O5S1 309.1741 11.6 1.21 Yes No n.e. YES 
C12-AE2S C16H34O6S1 353.2003 12.0 1.25 Yes No n.e. YES 
C12-AE3S C18H38O7S1 397.2265 12.9 1.29 Yes No n.e. YES 
C12-AE4S C20H42O8S1 441.2528 13.4 1.35 Yes No n.e. YES 
C12-AE5S C22H46O9S1 485.2790 13.5 1.39 Yes No n.e. YES 
C12-AE6S C24H50O10S1 529.3052 13.6 1.50 Yes No n.e. YES 
C12-AE7S C26H54O11S1 573.3314 13.4 n.d. Yes No n.e. YES 
 
  
  
 
 
  
C13-AE1S C15H32O5S1 323.1898 13.2 1.20 Yes No n.e. YES 
C13-AE2S C17H36O6S1 367.2160 13.5 1.24 Yes YES Yes YES 
C13-AE3S C19H40O7S1 411.2422 13.6 1.29 Yes No n.e. YES 
C13-AE5S C23H48O9S1 499.2946 13.8 1.38 Yes No n.e. YES 
C13-AE6S C25H52O10S1 543.3208 13.8 n.d. Yes No n.e. YES 
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Name Neutral formula 
Monoisotopic 
mass 
RP tR (min)  
HILIC tR 
(min) 
Plausible tR 
among the 
analogue series 
MS/MS 
data 
available 
MS/MS 
plausibility 
Tentatively 
identified 
C13-AE7S C27H56O11S1 587.3471 13.9 n.d. Yes No n.e. YES 
C13-AE8S C29H60O12S1 631.3733 13.9 n.d. Yes No n.e. YES 
 
  
  
 
 
  
C14-AE1S C16H34O5S1 337.2054 14.0 1.20 Yes No n.e. YES 
C14-AE2S C18H38O6S1 381.2316 14.2 1.22 Yes No n.e. YES 
C14-AE3S C20H42O7S1 425.2578 14.3 1.25 Yes No n.e. YES 
C14-AE4S C22H46O8S1 469.2841 14.3 n.d. Yes No n.e. YES 
C14-AE5S C24H50O9S1 513.3103 14.5 n.d. Yes No n.e. YES 
 
  
  
 
 
  
C16-AE1S C18H38O5S1 365.2367 14.9 n.d. Yes No n.e. YES 
C16-AE2S C20H42O6S1 409.2629 15.0 n.d. Yes No n.e. YES 
C16-AE3S C22H46O7S1 453.2891 15.0 n.d. Yes No n.e. YES 
C16-AE4S C24H50O8S1 497.3154 15.0 n.d. Yes No n.e. YES 
 
  
  
 
 
  
NPEO1-SO4 C17H28O5S1 343.1585 7.7 n.d. No No n.e. NO 
NPEO1-SO4 C17H28O5S1 343.1585 12.5 1.19 Yes No n.e. YES 
NPEO2-SO4 C19H32O6S1 387.1847 12.7 1.26 Yes No n.e. YES 
NPEO3-SO4 C21H36O7S1 431.2109 12.9 1.32 Yes No n.e. YES 
NPEO4-SO4 C23H40O8S1 475.2371 12.9 1.35 Yes No n.e. YES 
NPEO5-SO4 C25H44O9S1 519.2633 13.0 n.d. Yes No n.e. YES 
NPEO6-SO4 C27H48O10S1 563.2895 13.0 n.d. Yes No n.e. YES 
 
  
  
 
 
  
SPA-2DC C10H10O7S1 273.0074 5.7 n.d. No No n.e. NO 
SPA-5DC C13H16O7S1 315.0544 1.3 7.40 Yes No n.e.* YES 
SPA-6DC C14H18O7S1 329.0700 1.7 7.31 Yes No n.e. YES 
SPA-7DC C15H20O7S1 343.0857 5.4 n.d. No No n.e. NO 
SPA-7DC C15H20O7S1 343.0857 1.6 7.26 Yes Yes Yes YES 
SPA-8DC C16H22O7S1 357.1013 6.0 7.20 No No n.e. NO 
SPA-8DC C16H22O7S1 357.1013 3.0 7.20 Yes No n.e. YES 
SPA-10DC C18H26O7S1 385.1326 7.6 n.d. No No n.e. NO 
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Name Neutral formula 
Monoisotopic 
mass 
RP tR (min)  
HILIC tR 
(min) 
Plausible tR 
among the 
analogue series 
MS/MS 
data 
available 
MS/MS 
plausibility 
Tentatively 
identified 
SPA-12DC C20H30O7S1 413.1639 6.7 n.d. No No n.e. NO 
 
  
  
 
 
  
STA-1C C12H14O5S1 269.0489 3.0 n.d. Yes No n.e. YES 
STA-2C C13H16O5S 283.0646 4.7 n.d. Yes No n.e. YES 
STA-3C C14H18O5S1 297.0802 5.5 n.d. Yes No n.e. YES 
STA-4C C15H20O5S1 311.0959 6.0 n.d. Yes Yes Yes* YES 
STA-5C C16H22O5S1 325.1115 6.8 n.d. Yes Yes Yes YES 
STA-6C C17H24O5S1 339.1272 7.8 n.d. Yes No n.e. YES 
STA-7C C18H26O5S1 353.1428 8.0 n.d. No No n.e. NO 
STA-8C C19H28O5S1 367.1585 12.0 n.d. No Yes No NO 
STA-9C C20H30O5S1 381.1741 9.6 n.d. Yes Yes No NO 
STA-9C C20H30O5S1 381.1741 10.6 n.d. Yes Yes No NO 
 
  
  
 
 
  
C14-SAS C14H30O3S1 277.1843 13.3 1.72 n.e. No n.e. NO 
PEG-7EO C14H30O8 325.1868 13.6 n.d. n.e. Yes n.e. NO 
NPEO8-SO4 C31H56O12S1 651.3420 5.8 n.d. n.e. No n.e. NO 
benzenesulfonate C6H6O3S1 156.9965 2.6 1.87 Yes Yes Yes YES 
naphthalene-1-sulfonate C10H8O3S1 207.0121 5.8 1.85 Yes Yes Yes* YES 
2-chloro-4-amiNotoluene-5-
sulfonate 
C7H8Cl1N1O3S1 219.9841 5.9 n.d. n.e. No n.e. NO 
2-chloro-5-amiNotoluene-4-
sulfonate 
C7H8Cl1N1O3S1 219.9841 5.9 n.d. n.e. No n.e. NO 
n.d. not detected, n.e. not evaluated, * spectra available in MassBank 
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Suspect surfactants results - Positive ESI mode : 
Name Neutral formula 
Monoisotopic 
mass 
RP tR (min)  
HILIC tR 
(min) 
Plausible tR 
among the 
analogue series 
MS/MS 
data 
available 
MS/MS 
plausibility 
Tentatively 
identified 
C10-AEO-2 C14H30O3 247.2268 13.2 1.40 Yes Yes Yes YES 
C10-AEO-3 C16H34O4 291.2530 13.3 1.41 Yes Yes Yes YES 
C10-AEO-4 C18H38O5 335.2792 13.3 1.43 Yes Yes Yes YES 
C10-AEO-4 C18H38O5 335.2792 9.0 n.d. No No n.e. NO 
C10-AEO-5 C20H42O6 379.3054 13.4 1.45 Yes No Yes YES 
 
  
  
 
 
  
C11-AEO-2 C15H32O3 261.2424 13.8 1.40 Yes Yes Yes YES 
C11-AEO-3 C17H36O4 305.2686 13.85 1.40 Yes Yes Yes YES 
C11-AEO-4 C19H40O5 349.2949 13.9 1.41 Yes No n.e. YES 
 
  
  
 
 
  
C12-AEO-2 C16H34O3 275.2581 14.3 1.38 Yes No n.e. YES 
C12-AEO-3 C18H38O4 319.2843 14.3 1.39 Yes No n.e. YES 
C12-AEO-4 C20H42O5 363.3105 14.3 1.40 Yes No n.e. YES 
 
  
  
 
 
  
C13-AEO-2 C17H36O3 289.2737 14.4 1.38 Yes No n.e. YES 
C13-AEO-3 C19H40O4 333.2999 14.6 1.39 Yes No n.e. YES 
C13-AEO-4 C21H44O5 377.3262 14.7 1.40 Yes No n.e. YES 
 
  
  
 
 
  
C7DEA C12H25N1O3 232.1907 9.1 1.71 Yes Yes Yes* YES 
C9DEA C14H29N1O3 260.2220 11.2 1.65 Yes Yes Yes* YES 
C11DEA C16H33N1O3 288.2533 12.7 1.60 Yes Yes Yes* YES 
 
  
  
 
 
  
SPA-12DC C20H30O7S1 415.1785 5.6 2.52 n.e. No n.e. NO 
STA-15DC C27H42O7S1 511.2724 5.8 3.44 n.e. No n.e. NO 
C11-DATS C17H26O3S1 311.1675 1.9 n.d. n.e. No n.e. NO 
C11-SPC C17H26O5S1 343.1574 10.6 n.d. n.e. No n.e. NO 
n.d. not detected, n.e. not evaluated, * spectra available in MassBank 
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Results in sludge 
Target Analysis 
Screening of the sludge samples was performed. The method 
and the database for the evaluation of the data was the same as in the 
wastewater samples. The compounds detected at least once in the 
sludge samples of 2014 and 2015 are presented in Table 7. 
 
Table 7. Screening results of sludge samples 
 Compound name 
1 1 3 5(10)-estratrien-3  7?-diol/ 17a-ESTRADIOL (E2) 
2 2-Aminobenzimidazole 
3 2-OH-Benzothiazole 
4 2-phenethylamine 
5 4-androsten-3 17-dione  (A4) 
6 4-Me-Benzotriazole /5-Me-Benzotriazole 
7 4-nonylphenol (4-NP) 
8 4-nonylphenol-mono ethoxylate 
9 4-Nonylphenoxy acid 
10 4-tert-octylphenol (4-t-OP) 
11 8-OH-Mirtazapine 
12 Aceclidine 
13 Acetochlor-OXA / Alachlor-OXA 
14 Adenine 
15 Adenosine 
16 Aliskiren 
17 Allopurinol  
18 Altretamine 
19 Amantadine 
20 Amisulpride 
21 amitryptyline  
22 Atazanavir 
23 Atenolol acid (Metoprolol acid) 
24 Azoxystrobin 
25 Azoxystrobin acid 
26 benzododecinium (benzyl-dimethyl dodecyl ammonium 
27 Benzotriazole (BTR) 
28 Benzyl butyl phthalate 
29 Bethanidine 
30 Bis-(2-ethylhexyl) phthalate 
31 Bisphenol A (BPA) 
32 Buspirone 
33 Carbachol 
34 Carbamazepine  
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35 Celiprolol 
36 Cetirizin 
37 Cimetidine 
38 Cinnarizine 
39 Ciprofloxacin 
40 Citalopram 
41 Citalopram amide 
42 Clarithromycin 
43 Climbazol 
44 Cortisol  
45 Cotinine 
46 Cyproconazole 
47 D L-N O-Didesmethylvenlafaxine 
48 D617_metabolite_verapamil 
49 DADMAC C10:C10 
50 deacetyl diltiazem 
51 Desvenlafaxine (O-Desmethylvenlafaxine) 
52 Diethyl phthalate 
53 Difenoconazole 
54 Di-n-butyl phthalate 
55 Di-n-octyl phthalate 
56 Dioxacarb 
57 Diphenhydramine 
58 DMPEA (HMA) 
59 EDDP 
60 Eprosartan 
61 Esmolol 
62 Fludioxonil 
63 Flufenamic acid 
64 Fluometuron 
65 Fluoxetine 
66 Formetanate 
67 Fuberidazole 
68 Gabapentin 
69 Galaxolide 
70 Galaxolidone 
71 Harman 
72 Harmine 
73 Histamine 
74 Irbesartan 
75 Isoconazole 
76 Lacosamide 
77 Lamotrigin 
78 Levofloxacin 
79 MDA 
80 Mefenamic acid 
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81 Memantine 
82 Metazachlor-ESA 
83 Methprene  
84 Metoprolol 
85 Mirtazapine 
86 Morantel 
87 Morphine 
88 N-Desmethyl Citalopram 
89 N-Desmethylvenlafaxine 
90 Nicotinamide 
91 Niflumic acid 
92 Norcitalopram 
93 Norethisterone acetate 
94 Norfenefrine 
95 Norfloxacin 
96 Normirtazapine 
97 Normorphine 
98 Nortriptyline 
99 Octocrylene 
100 Ofloxacin 
101 Orphenadrine 
102 Penconazole 
103 PFOS 
104 Phenoxybenzamide 
105 Phentermine 
106 Pioglitazone 
107 Piperonylbutoxide 
108 Pregabalin 
109 Progesterone 
110 Propafenone 
111 Propham 
112 Propranolol 
113 Pymetrozine 
114 Ranitidine 
115 Roxithromycin 
116 Salicylic acid 
117 Seneciphylline-N-oxide 
118 Sertraline 
119 Sotalol 
120 Telmisartan 
121 Temephos 
122 Thebacon 
123 Thiabendazole 
124 Tralkoxydim 
125 Tramadol 
126 Tributylamin 
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127 Triclocarban 
128 Triclosan 
129 Triethylphosphate 
130 Triphenylphosphate 
131 Tyramine 
132 Ursodeoxycholic acid 
133 Valsartan 
134 Venlafaxine 
135 Verapamil 
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2nd Study – Batch experiment and identification of 
transformation products (TPs) 
Emerging pollutants, once released in the environment, they 
reach wastewater treatment plants, where they are subject to various 
processes for their degradation. These processes can be either 
biological or chemical and they end up to transformation products, 
which have different physicochemical properties and different 
toxicity than the parent compounds. 
It is important to study the occurrence and toxicity of the 
transformation products formed during the wastewater treatment 
procedure, since they are released in the environment. 
The biological degradation is the main technique for the 
elimination of the emerging pollutants. During the disinfection 
procedure of the treatment (tertiary treatment), chlorination is the 
main technique.  
 
Chlorination experiments 
Although the primary purpose of chlorination is the 
elimination of micropollutants via oxidation, several investigations 
have shown that chlorine reacts with micropollutants leading in the 
production of undesired by-products. Recently, the identification and 
the evaluation of chlorination by-products has been a topic of 
growing interest, since these by-products may pose an 
environmental or human health risk, even higher than their parent 
compounds do. 
Initially, experiments were conducted in ultrapure water and 
effluent samples from the main WWTP in Greece, Psyttaleia, in order 
to investigate the degradation of benzotriazoles and benzothiazoles 
in different chlorination conditions [applied molar ratio of NaOCl and 
the target contaminant (m.r.), reaction’s contact time, pH value of the 
reaction’s solution and the influence of total suspended solids (TSS) 
presence]. Thereafter, UHPLC High Resolution (HR) MS technique 
was used in order to look into the formation of possible by-products 
in the ultrapure water chlorinated samples and then verify their 
occurrence in spiked wastewater samples treated with chlorine. 
Information on the experimental protocol of the chlorination batch 
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experiment can be found by Nika et al. (2015) and the results of the 
chlorinated by-products are presented in Table 8. 
 
Table 8. Transformation products, along with their parent compound, which 
were detected and structurally elucidated in chlorination batch experiments. 
Parent Compound 
Transformation 
product name 
Proposed Structure 
Molecular 
formula 
5,6-dimethyl-1H-
benzotriazole 
(XTRi) 
 
 
 
C8H9N3 
4-chloro-XTRi or 
7-chloro-XTRi 
   
C8H8ClN3 
4-hydroxy-XTRi 
or 7-hydroxy-
XTRi 
    
C8H9N3O 
 
4,7-di-hydro-
XTRi 
 
C8H9N3O2 
6-methyl-BTR-5-
carbaldehyde or 
5-methyl-BTR-6-
carbaldehyde  
C8H7N3O 
 
2-aminbenzothiazole 
(2-amino-BTH) 
 
 
 
C7H6N2S 
2-amino-6-
chloro-BTH 
 
C7H5ClN2S 
2-amino-5,6-di-
chloro-BTH 
 
C7H4Cl2N2S 
2-amino-5,6-di-
hydroxy-BTH 
 
C7H6N2O2S 
 
2-amino-6-
chloro-5-
hydroxy-BTH 
 
C7H5ClN2OS 
2-[2-(BTH-2-
yl)hydrazin-1-yl]-
6-chloro-BTH 
 
C14H9ClN4S2 
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Biotransformation experiments 
Since wastewater treatment is mainly concerned with 
biodegradation, the detection and identification of biotransformation 
TPs is a necessary but at the same time challenging task which 
requires the use of modern high-resolution mass spectrometry (HR-
MS) systems and appropriate analysis strategies. 
Formed TPs differ to some extent in their environmental 
behavior and ecotoxicological profile to their related parent 
compounds. Despite low concentrations, the effects of these 
substances in the environment and human health cannot be 
excluded. 
In table 9, the biotransformation products of emerging 
pollutants found in influent wastewater samples are presented. The 
batch experiments are presented by Beretsou et al. (2015). 
 
Table 9. Transformation products, along with their parent compound, which 
were detected and structurally elucidated in biotransformation experiments. 
Parent Compound 
Transformation 
product name 
Proposed Structure 
Molecular 
formula 
Lidocaine 
(LD) 
 
 
C14H22N2O 
LDC 207 
 
C12H18N2O 
LDC 251 
 
C14H22N2O2 
LDC 219 
 
C13H18N2O 
LDC 233 
 
C13H16N2O2 
LDC 265 n.p.* C14H20N2O3 
Ranitidine 
(RAN) 
 
 
C13H22N4O3S 
RAN 286 (three 
chromatographic 
peaks) 
n.p. C11H15N3O4S 
RAN 301 a 
 C12H20N4O3S 
RAN 301 b 
 
RAN 302 (two n.p. C11H15N3O5S 
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chromatographic 
peaks) 
RAN 316 (three 
chromatographic 
peaks) 
n.p. 
C13H21N3O4S 
 
RAN 317 (two 
chromatographic 
peaks) 
n.p. C12H20N4O4S 
RAN 331 a (S-
oxide) 
 C13H22N4O4S 
RAN 331 b (N-
oxide) 
 
Metformin 
 
 
C4H11N5O 
Guanylurea 
 
C2H6N4O 
Atorvastatin 
(ATR) 
 
 
 
C33H35FN2O4 
 
ATR 515 
 
C31H31FN2O4 
ATR 471 
 
C29H27FN2O3 
ATR 487 (two 
chromatographic 
peaks, two 
isomers) 
 
C29H27FN2O4 
Citalopram 
(CTR) 
 
 
 
C20H21FN2O 
CTR 311 
(DesmethylCTR) 
 
C19H19FN2O 
CTR 329 
(DesmethylCTR 
amide) 
 
C19H21FN2O2 
CTR 330 
(DesmethylCTR 
carb. acid) 
 
C19H20FNO3 
CTR 339A 
(3-oxo-CTR) 
 
C20H19FN2O2 
CTR 339B n.p. C21H23FN2O 
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CTR 341 
(CTR-N-oxide) 
 
C20H21FN2O2 
CTR 343 
(CTR amide) 
 
C20H23FN2O2 
CTR 344 
(CTR carb. acid) 
 
C20H22FNO3 
CTR 355 
 
C20H19FN2O3 
CTR 357 
 
C20H21FN2O3 
CTR 359A 
 C20H23FN2O3 
CTR 359B 
(Amide of CTR-N-
oxide) 
 
CTR 360A 
(Carb. acid of 
CTR-N-oxide) 
 
C20H22FNO4 
CTR 360B 
 
n.p.: no structure could be proposed 
 
Retrospective suspect screening of citalopram and its bio-TPs 
in wastewater samples 
Retrospective suspect screening was performed in order to 
evaluate the occurrence of the identified TPs during the 
biotransformation experiments in real wastewater samples.  
The parent compound CTR along with its primary metabolite 
N-desmethyl CTR (CTR 311) was found in all evaluated wastewater 
samples. 3-oxo-CTR (CTR 339A) was the second most frequently 
detected compound in influent and effluent wastewater samples. 
CTR-N-oxide (CTR 341) was also detected in all effluents and in 7 out 
of 16 the influents. This fact can be easily explained since this 
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compound is also a human metabolite. Finally, the compounds CTR 
amide (CTR 343) and CTR carboxylic acid (CTR 344) were only found 
in 3 influent and 1 effluent samples, respectively, as a result of 
biotransformation of CTR in activated sludge. 
The presence of TPs of CTR in wastewater samples can be thus 
attributed to a double contribution: (1) the direct input from human 
excreted metabolites in IWW and (2) the action of microorganisms 
during wastewater treatment, biodegrading CTR in known and 
unknown TPs. 
 
Risk Assessment 
In order to assess the environmental impact of these projects’ 
findings, toxicity calculations with ECOSAR software (Ecological 
Structure Activity Relationship, 
http://www.epa.gov/oppt/newchems/tools/21ecosar.htm, v. 1.11, 
last accessed October 2015) were performed, so as to obtain an 
insight on the acute toxicity of the identified transformation products 
(TPs) on three classes of aquatic organisms; fish, algae and daphnia 
magna. This program provides the probable toxicity of a compound 
according to its octanol/water partition coefficient (Kow) value and its 
structure similarity with other compounds whose toxicity in aquatic 
environment has been previously estimated. 
 
Pharmaceuticals, drugs of abuse and related metabolites 
For target compounds detected at least once toxicity data 
(EC50 or LC50) for three different trophic levels (algae, daphnids and 
fish) has been collected either through literature search or from 
ECOSAR program which is used from the US EPA. In either case the 
lowest short period toxicity values were collected in order to take 
into consideration the worst case scenario. According to the 
Technical Guidance Document of the European Commission, the risk 
quotient (RQ) is calculated as the maximum Measured 
Environmental Concentration (MEC) divided to the Predicted No 
Effect Concentration (PNEC), which is EC50 or LC50 value divided to 
1000 in case short-term toxicity data is used. 
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Table 10 summarizes the toxicity data, the maximum measured 
concentration and the risk quotients. Risk quotients above 1 indicate 
potential environmental risk. 
 
Table 10. Estimation of Risk Quotients, RQ (MEC/PNEC) for the emerging organic 
contaminants contained in treated wastewater. 
Emerging contaminants  RQ values 
  Fish  Daphnia magna  Algae 
Pharmaceuticals  
Amoxicillin  <1  <1  44 
Atorvastatin  NA <1  NA 
Azithromycin  <1  <1  15 
Caffeine  <1  <1  927 
Clarithromycin <1  <1  31 
Clofibric acid  <1  1.9 <1  
Diclofenac 1.3 <1  <1  
Fluoxetine <1  <1  1.2 
Gemfibrozil  1.9 <1  <1  
Ofloxacin <1  <1  9.8 
Pentobarbital <1  <1  39 
Phenobarbital  <1  <1  18 
Sertraline <1  <1  2.4 
Sulfamethoxazole <1  <1  3.5 
Theophylline <1  <1  38 
Tramadol 7.5 13 1 
Tylosin NA <1  1.2 
Valsartan <1  <1  2.4 
Venlafaxine <1  <1  1.1 
Endocrine disrupters  
4-t-octylphenol  1.4 <1  <1  
Bisphenol A 7 <1  1.1 
Nonylphenol  835 <1  30 
Nonylphenol diethoxylate 54 <1  31 
Nonylphenol monoethoxylate 32 <1  22 
Triclosan 27 <1  4914 
Benzotriazoles 
Tolytriazole <1  <1  1.5 
Artificial sweeteners  
Sucralose  <1  <1  113 
Siloxanes 
Octamethylcyclotetrasilane 20 NA NA 
Decamethylcyclopentasilane  NA 2076 NA 
Dodecamethylcyclohexasilane NA NA 30 
*NA, not available 
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Chlorination experiments 
The prediction of the acute toxicity of the proposed 
chlorination by-products of 5,6-dimethyl-1H-benzotriazole (XTRi) 
and 2-aminobenzothiazole (2-amino-BTH) was realized by ECOSAR 
software and the calculated values, LC50 (median lethal 
concentration) for fish and EC50 (median effective concentration) for 
algae, are listed in Table 11. XTRi and its by-products were 
considered as benzotriazoles structure-alike chemicals, while 2-
amino-BTH and its produced chlorination by-products were 
considered as unhindered anilines-structure alike chemicals. As it 
can be concluded from the results, the chlorinated derivatives of both 
XTRi and 2-amino-BTH are more toxic than their parent compounds 
while the hydroxylated derivatives were proved to be less hazardous. 
The toxicity effect of 2-[2-(BTH-2-yl)hydrazin-1-yl]-6-chloro-BTH is 
not presented because this chemical may not be soluble enough to 
measure the predicted values. Although these results are not coming 
from real toxicity experiments, they can be interpreted as an 
indication of the potential environmental risk of the identified by-
products. 
 
Table 11.  ECOSAR results for a) 2-amino-BTH, b) XTRi and their identified 
chlorination by-products respectively. 
a) 
Organism 
(96 h) 
Predicted mg/L (EC 50 for fish and LC 50 for algae) 
XTRi 
4-chloro-XTRi or7-
chloro-XTRi 
4-hydroxy-XTRi or 7-
hydroxy-XTRi 
4,7-di-hydro-
XTRi 
6-methyl-BTR-5-carbaldehyde 
or 5-methyl-BTR-6-
carbaldehyde 
Fish  9.376 5.238 18.524 36.246 27.872 
Green Algae  2.484 1.626 4.418 7.782 6.157 
b) 
Organism 
(96 h) 
Predicted mg/L (EC 50 for fish and LC 50 for algae) 
2-amino-BTH 
2-amino-6-
chloro-BTH 
 
2-amino-5,6-di-
chloro-BTH 
2-amino-5,6-
di-hydroxy-
BTH 
2-amino-6-
chloro-5-
hydroxy-BTH 
Fish 21.349 9.336 3.940 120.828 21.913 
Green Algae 1.707 1.474 1.229 3.505 2.084 
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Biotransformation experiments 
To estimate the ecotoxicological risk for the aquatic biota due 
to citalopram (CTR) and its TPs, risk quotients (RQ) were calculated 
for the Measured Environmental Concentrations (MEC). Predicted No 
Effect Concentration (PNEC) was also calculated by dividing the 
lowest short-term L(E)C50 available in the literature or as it was 
estimated by ECOSAR program, by an appropriate assessment factor 
(AF) of 1000, since no long-term toxicity data were available. For 
CTR, EC50 values for daphnia magna and algae were obtained from 
an already published study (Christensen et al. 2007). For RQ values 
greater than 1, the ecotoxicological risk for the aquatic environment 
is raised and further research is needed whereas, in cases where RQ 
is lower than 1, no ecotoxicological risk is expected for the aquatic 
biota. 
Semi-quantitation of the identified TPs was performed in an 
effluent wastewater sample, collected in March 2015 from Psytallia, 
in order to obtain the MEC values. The concentrations of CTR and its 
TPs, whose structure was confirmed either through the analysis of a 
reference standard or by library matching, in the effluent sample, 
PNEC values (along with the used assessment factors) and RQ 
deemed for each analyte are presented in Table 12. According to 
these results, both CTR and its TPs have RQ lower than 1 and 
therefore no risk is expected. However, it should be noted that, given 
the mixture of these compounds with the same pharmacological 
mechanisms, additive or even synergistic effects could be expected, 
posing real environmental threat higher than the calculated one. 
 
Table 12: Risk assessment data for CTR and its confirmed TPs. 
Compound 
MEC 
(μg L−1) 
PNEC 
(μg L−1) 
Algae 
RQ 
Algae 
PNEC 
(μg L−1) 
Daphnia Magna 
RQ 
Daphnia 
Magna 
PNEC 
(μg L−1) 
Fish 
RQ 
Fish 
CTR 1.010 1.60
a
 0.630 20
a
 0.05 4.47 0.226 
CTR 311 0.329 0.486 0.677 0.838 0.393 5.88 0.056 
CTR 339 a 0.023 1.92 0.012 02.77 0.008 21.3 0.001 
CTR 341 0.048 1.32 0.036 0.200 0.024 15.0 0.003 
CTR 343 0.010 1.40 0.007 2.11 0.005 15.9 0.001 
CTR 344 0.008 2.21 0.004 4.33 0.002 28.5 0.001 
aValues retrieved from the literature (Christensen et al. 2007) 
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Conclusion and Future Research  
An RQ based approach was applied to evaluate the potential 
threat due to the existence of emerging contaminants in treated 
wastewater. This method is simple in use, it is applied to 
micropollutants that are known to be present in the aquatic 
environment and it is based on actual measurements. It could be 
used as starting point for organizations just beginning to monitor 
emerging contaminants and as a screening diagnostic tool for 
assessing specific sites. According to the results for Greece, EDCs 
presented the highest risk of all emerging pollutants in both 
wastewater and rivers. Triclosan (in algae) and nonylphenol (in fish) 
had the highest RQs among EDCs, while caffeine (in algae) had the 
highest RQ of all studied pharmaceuticals. The class of emerging 
contaminants that had the highest contribution to the mixture 
toxicity, in both wastewater and rivers, was EDCs. Despite the fact 
that the rivers with low flows presented the highest ecological threat 
due to the presence of micropollutants, a possible ecological threat 
cannot be excluded even for rivers with high dilution factors (up to 
2388). In the near future, researchers should deepen on assessment 
of single and mixture toxicity of emerging contaminants and their 
metabolites to different aquatic organisms. Environmental engineers 
should think again STPs design aiming to micropollutants removal, 
while authorities should update relevant legislation, setting limit 
values for specific emerging contaminants (Thomaidi et al., 2015).  
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